hCG vs Melanotan II

Glycoprotein hormone binding LH receptor on Leydig cells; stimulates testosterone production; prevents testicular atrophy during TRT; maintains spermatogenesis via FSH-like activity

Human chorionic gonadotropin (hCG) is a glycoprotein hormone that acts as a functional analogue of luteinizing hormone (LH), binding to LH receptors on Leydig cells in the testes and granulosa cells in the ovaries to stimulate steroidogenesis. In men, hCG stimulates testicular testosterone production directly, making it a widely used clinical tool for hypogonadotropic hypogonadism, male fertility support, and preservation of testicular function alongside testosterone replacement therapy. Clinical research demonstrates hCG effectiveness for improving testosterone levels and sperm parameters in males with gonadotropin deficiency, as well as for triggering final oocyte maturation in IVF protocols. hCG is an FDA-regulated biologic available in multiple approved formulations; use requires physician supervision due to dose-dependent effects on testosterone, estradiol, and reproductive signaling. hCG dosage in TRT support: in men using testosterone replacement therapy, hCG is prescribed to prevent testicular atrophy and maintain intratesticular testosterone levels needed for spermatogenesis. Typical clinical doses range from 250 to 500 IU subcutaneously administered 2–3 times per week, though protocols vary by provider and individual response. At higher doses, hCG's stimulation of testicular testosterone can also increase aromatization to estradiol — a clinically relevant consideration in TRT management requiring estrogen monitoring. hCG vs gonadorelin: both are used in men's health for testicular preservation alongside TRT, but they act at different axis levels. hCG acts directly on Leydig cell LH receptors, bypassing the pituitary entirely — a direct trophic signal to the testes. Gonadorelin acts upstream at the pituitary to stimulate endogenous LH and FSH release, preserving the full hypothalamic-pituitary-gonadal axis including FSH-driven spermatogenesis. For men prioritizing sperm production, gonadorelin's preservation of FSH signaling offers a potential advantage; for men primarily focused on testicular volume and intratesticular testosterone maintenance, hCG provides a well-validated, direct approach. Telehealth and men's health providers offering hCG and gonadorelin protocols are listed in the PeptideBase directory.

Synthetic melanocortin receptor agonist (MC1R-MC5R); activates MC4R for erectile function/libido; MC1R for melanogenesis; MC3R for appetite suppression

Melanotan II is a synthetic analogue of alpha-melanocyte-stimulating hormone (alpha-MSH), a neuropeptide that activates melanocortin receptors (MC1R, MC4R) involved in pigmentation, sexual arousal, and appetite regulation. By agonizing MC4R receptors in the central nervous system, melanotan II promotes erectile function and sexual arousal through a centrally mediated pathway, distinct from the peripheral vasodilatory mechanism of PDE5 inhibitors. An early randomized controlled trial demonstrated significant improvements in erectile function and sexual desire in men with organic erectile dysfunction, and subsequent reviews have characterized the melanocortin receptor class as a pharmacological target for sexual dysfunction. Melanotan II is not approved by the FDA or any major regulatory agency for any indication; it is a research compound associated with significant off-target effects, and a related compound (bremelanotide, marketed as PT-141) holds FDA approval for hypoactive sexual desire disorder in pre-menopausal women. Melanotan II vs PT-141: bremelanotide (PT-141) was developed directly from the melanotan II research program as a cleaner successor compound. PT-141 was designed to retain the MC4R-mediated sexual response effects while reducing the tanning (MC1R) and nausea side effects that characterize melanotan II. The key practical distinction is that PT-141 has completed Phase 3 trials and holds FDA approval, while melanotan II remains an unapproved research compound. Melanotan II is associated with more pronounced side effects than its successor — including facial flushing, nausea, spontaneous erections, and significant skin pigmentation from MC1R activation — which contributed to its replacement by the more selective bremelanotide in clinical development. Research doses in published studies have used subcutaneous administration in the range of 0.5–1 mg per dose; the side effect profile is dose-dependent, with nausea being the most commonly reported adverse event. Melanotan II has no approved clinical use in any jurisdiction; individuals interested in melanocortin-based sexual health compounds are better served by consulting providers offering FDA-approved PT-141 (bremelanotide), listed in the PeptideBase directory.